AIkido Pharma Inc. (Nasdaq: AIKI), a US-based biotechnology company, concentrating on developing small-molecule anti-cancer therapeutics, announced on Friday that it has established a wholly owned financial services subsidiary.
The company has set up the subsidiary with the aim of making strategic investments and acquisitions across the fintech and financial services industries. It is intended to be the focus of a long-range plan to diversify the company's business beyond biotechnology, in order to decrease volatility and mitigate risk while increasing revenue and improving shareholder value.
The company said that the new subsidiary is to use the extensive capital markets expertise of the company's board of directors to identify investment opportunities and acquisition targets in wealth management, investment banking, alternative investments, and asset management with the aim of transforming and optimising operations with a synergistic and accretive business model. The firm said that it is in the process of hiring additional top-tier talent to implement the strategy.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval